GKSL Q4FY26 Monitoring Report: ₹250.80 Crore IPO Proceeds Utilized as per Plan
Gujarat Kidney and Super Speciality Limited's Q4FY26 monitoring report confirms ₹250.80 Crore IPO proceeds were utilized as per the offer document. Key uses include hospital acquisition, subsidiary stake purchase, capex, and debt repayment. Unutilized funds stand at ₹13.04 Crore. The report by Brickwork Ratings indicates no deviations in fund utilization.
This is a standard regulatory filing confirming adherence to the utilization plan of IPO funds. It does not introduce new material information that would significantly impact the company's valuation or investor sentiment.
The report is a routine monitoring agency submission confirming that the utilization of IPO proceeds is as per the offer document. It does not contain any new financial performance data or significant positive or negative developments.
Gujarat Kidney and Super Speciality Limited (GKSL) has submitted its Second Monitoring Agency Report for the quarter ended March 31, 2026, prepared by Brickwork Ratings (BWR). The report details the utilization of funds raised through a Fresh Issue of Equity Shares, which aggregated to ₹250.80 Crore.
The company has confirmed that all utilization of funds is in line with the disclosures made in the Offer Document. Key utilization areas include proposed acquisition of Parekhs Hospital at Ahmedabad (₹77.00 Crore), part-payment for the acquired “Ashwini Medical Centre” (₹12.40 Crore), acquisition of additional shareholding in subsidiary “Harmony Medicare Private Limited” (₹10.78 Crore), funding capital expenditure for a new hospital in Vadodara (₹30.09 Crore), buying robotics equipment (₹6.83 Crore), and repayment of secured borrowings (₹1.20 Crore). A significant portion of ₹87.44 Crore is allocated for funding inorganic growth through unidentified acquisitions and General Corporate Purposes (GCP), with ₹74.82 Crore utilized as of March 31, 2026. Issue expenses amounted to ₹25.05 Crore, with ₹24.63 Crore utilized.
As of March 31, 2026, the unutilized proceeds amounted to ₹12.62 Crore for inorganic growth/GCP and ₹0.42 Crore for issue expenses. The remaining unutilized funds are held in HDFC Bank accounts. The report also notes that while the acquisition of Parekhs Hospital, part-payment for Ashwini Medical Centre, acquisition of shares in Harmony Medicare, and repayment of borrowings are completed, the setting up of a new hospital in Vadodara, purchase of robotics equipment, funding inorganic growth, and issue expenses are ongoing projects with completion expected up to the Financial Year 2026-27.
The utilized amount for General Corporate Purposes as of March 31, 2026, was ₹24.78 Crore, which is within the 25% limit stipulated by SEBI ICDR Regulations. The report confirms no deviation from the objects stated in the Offer Document.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.